4 citations
,
July 2023 in “Nature Medicine” The FDA approved a new Pfizer drug for hair loss in teens.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
A lotion with tretinoin, minoxidil, and betamethasone valerate helped treat a woman's skin infection.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
January 2024 in “Journal of dermatology and skin science” Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
1 citations
,
April 2024 in “The Journal of Dermatology” Untreated epidermolysis bullosa acquisita can cause total hair and nail loss.
15 citations
,
April 1997 in “Muscle & Nerve” 5 citations
,
April 1997 in “Muscle & Nerve” 18 citations
,
January 2021 in “Theranostics” The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.
54 citations
,
May 2019 in “Multiple Sclerosis and Related Disorders” Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.
Biorregulatory therapy significantly improved the dog's health, reversing previous issues and eliminating the need for ongoing medication.
May 2024 in “Frontiers in Medicine” Targeted immunological therapies offer safer and more effective treatments for skin conditions like eczema and psoriasis.
April 2023 in “Journal of Pakistan Medical Association” Baricitinib is effective in promoting hair growth in severe alopecia areata.
July 2022 in “British Journal of Dermatology” June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
September 2019 in “Journal of Investigative Dermatology” Targeted therapy with Ustekinumab significantly improved a skin condition called ILVEN, which is caused by mutations in the CARD14 gene.
December 2013 in “Nursing2023” The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
November 2010 in “Clin-Alert” Monitoring for adverse effects in clinical treatments is crucial.
Infliximab was effective in treating a scalp condition that did not respond to other treatments.
3 citations
,
August 2025 in “Advanced Therapeutics” Engineered cytokines show promise for improving tissue healing and safety in regenerative medicine.
44 citations
,
May 2023 in “MedComm” PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.
3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
June 2016 in “Annals of the rheumatic diseases” Methotrexate is effective for treating rheumatoid arthritis but requires regular monitoring.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.
February 2026 in “Molecules” BBR-SA nanomedicine is a safe and effective treatment for breast cancer.
September 2025 in “Frontiers in Pharmacology” The gel shows strong potential for effectively treating pressure ulcers.
June 2025 in “Preprints.org” Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.
November 2025 in “Mendeley Data” Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.